Idogen presents at Börsveckans Småbolagsdag February 19, 2020

Idogen’s CEO will present the company at Börsveckans Småbolagsdag which will take place at Operaterassen in Stockholm February 19, 2020.

Warmly welcome to you who are interested in Idogen and our innovative cell therapy!


Go to Financial Hearing’s website for registration
 

For additional information, please contact:
Anders Karlsson, CEO Idogen AB
Tel: +46 (0) 709 18 00 10                                                                         
E-mail: anders.karlsson@idogen.com

Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com

Tags:

About Us

Idogen AB (Spotlight Stock Market: IDOGEN) is a Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues. Idogen’s intention is to revolutionize the treatment of several disorders in which the body’s immune system does not function as it should, and for which there is a major unmet medical need – such as in autoimmune diseases, organ transplant rejection and in patients who have developed anti-drug antibodies.

Subscribe

Documents & Links